

Usage of Biologic & Biosimilar Products

Reference Number: RDF2201-24

Date of Response: 17/01/24

Further to your Freedom of Information Act request, please find the Trust's response(s) below:

Please be aware that the Royal Devon University Healthcare NHS Foundation Trust (Royal Devon) has existed since 1st April 2022 following the integration of the Northern Devon Healthcare NHS Trust (known as Northern Services) and the Royal Devon and Exeter NHS Foundation Trust (known as Eastern Services).

Q1. Could you please provide the numbers of patients treated by the rheumatology department (for any condition) in the last 3 months with the following drugs:

Drug Name	Count
Abatacept [Orencia]	33
Adalimumab [Humira]	29
Adalimumab Biosimilars	354
Apremilast [Otezla]	8
Baricitinib [Olumiant]	102
Bimekizumab [Bimzelx]	0
Certolizumab [Cimzia]	82
Etanercept [Enbrel]	8
Etanercept Biosimilars	146
Filgotinib [Jyseleca]	50
Golimumab [Simponi]	108
Guselkumab [Tremfya]	* <5
Infliximab [Remicade]	* <5
Infliximab Biosimilars	24
Ixekizumab [Taltz]	24
Risankizumab [Skyrizi]	0
Rituximab [MabThera]	0
Rituximab Biosimilars	34
Sarilumab [Kevzara]	11
Secukinumab [Cosentyx]	56
Tocilizumab [Ro Actemra]	0
Tocilizumab Biosimilars	75
Tofacitinib [Xeljanz]	25
Upadacitinib [Rinvoq]	111
Ustekinumab [Stelara]	* <5

Q2. Could you please provide the numbers of patients treated for Axial Spondyloarthritis (axSpA) ONLY in the last 3 months with the following drugs.

Drug Name	Count
Adalimumab [Humira]	6
Adalimumab Biosimilars	43

Certolizumab [Cimzia]	7
Etanercept [Enbrel]	*<5
Etanercept Biosimilars	*<5
Golimumab [Simponi]	0
Infliximab [Remicade]	0
Infliximab Biosimilars	*<5
Ixekizumab [Taltz]	*<5
Secukinumab [Cosentyx]	*<5
Tofacitinib [Xeljanz]	0
Upadacitinib [Rinvoq]	13

NB: Last 3 months – Oct-23 to Dec-23

Section 40 (2) - Less than five - *<5

Please note that where activity is 5 or less than 5, the Trust is unable to provide the exact information. We consider the data exempt on the following grounds:

The Trust considers that disclosure of the information risks identifying individuals. The reason for this is that the number of patients for which this applies is exceptionally low. This and the fact that the data requested relates to the RDUH Health NHS Trust only and therefore relates to patients treated in a specific location (rather than covering a larger geographical area), increases the risk of identification or self-identification.

The Trust's view is that s.40(2) is applicable because disclosure of information which could lead to a patient being identified would be a breach of the patient's rights under the Data Protection Act.